OCUGEN, INC. Shareholders' Equity
OCUGEN, INC. (OCGN) had Shareholders' Equity of -$16.56 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent -$16.56M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $5.80M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$12.17M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $3.53M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$16.56M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.80M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | -$12.17M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $3.53M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $3.05M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $15.91M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $29.63M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $40.63M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $16.93M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $30.26M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $40.56M 10-K · filed 2026-03-04 | |
| 2023-09-30 | $49.80M 10-Q · filed 2024-11-14 | $58.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $59.24M 10-Q · filed 2024-11-14 | $70.28M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $64.90M 10-Q · filed 2024-11-14 | $75.80M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $73.98M 10-K · filed 2025-03-05 | $84.05M 10-K · filed 2023-02-28 |
| 2022-09-30 | $85.69M 10-K · filed 2024-04-16 | $95.30M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $106.48M 10-K · filed 2024-04-16 | $114.11M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $125.52M 10-K · filed 2024-04-16 | $131.13M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $91.20M 10-K · filed 2024-04-16 | $95.82M 10-K · filed 2022-02-28 |
| 2021-09-30 | $107.11M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $116.41M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $46.49M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $21.55M 10-K · filed 2023-02-28 | $21.55M 10-K · filed 2021-03-19 |
| 2020-09-30 | $14.42M 10-Q · filed 2021-11-09 | $14.42M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $14.62M 10-Q · filed 2021-11-09 | $14.62M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $7.30M 10-Q · filed 2021-11-09 | $7.30M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $11.02M 10-K · filed 2022-02-28 | $11.02M 10-K · filed 2020-03-27 |
| 2019-09-30 | -$13.09M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | -$6.11M 10-Q · filed 2020-11-06 | -$8.73M 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$18.61M 10-Q · filed 2020-11-06 | -$5.53M 10-Q · filed 2019-05-15 |
| 2018-12-31 | -$12.71M 10-K · filed 2022-02-28 | -$458.00K 10-K · filed 2019-03-22 |
| 2018-09-30 | -$7.08M 10-Q · filed 2019-11-12 | -$9.68M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$5.37M 10-Q · filed 2019-11-12 | -$23.44M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$345.39K 10-Q · filed 2019-11-12 | -$20.07M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $4.43M 10-K · filed 2020-03-27 | -$11.27M 10-K · filed 2018-03-15 |
| 2017-09-30 | -$4.81M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $806.00K 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $6.97M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $13.57M 10-K · filed 2019-03-22 | |
| 2016-09-30 | $4.04M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $12.89M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $20.59M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $28.20M 10-K · filed 2018-03-15 | |
| 2015-09-30 | $36.18M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $43.87M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $51.22M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $54.21M 10-K · filed 2017-03-16 | |
| 2013-12-31 | -$75.55M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |